Modulators of alpha-1 antitrypsin

US12331057B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Upul K. Bandarage · Lexington, US
• Cavan McKeon Bligh · Somerville, US
• Diane Boucher · Boston, US
• Michael Boyd · Winchester, US
• Michael Aaron Brodney · East Lyme, US
• Michael P. Clark · Maineville, US
• Veronique Damagnez · Cambridge, US
• Lev Tyler Dewey Fanning · San Marcos, US
• Robert Francis Fimognari · Brookline, US
• Gabrielle Simone FLEMING · Boston, US
• Kevin James GAGNON · Acton, US
• Pedro Manuel GARCIA BARRANTES · Melrose, US
• Robert Daniel GIACOMETTI · Malden, US
• Simon Giroux · Cambridge, US
• Ronald Grey, Jr. · Mansfield, US
• Samantha Guido · Quincy, US
• Amy Beth HALL · Wellesley, US
• Sarah Carol HOOD · Worcester, US
• Dennis James Hurley · San Marcos, US
• Mac Arthur Johnson, Jr. · Derry, US
• Peter Jones · Sharon, US
• Sarathy KESAVAN · Quincy, US
• Mei-Hsiu LAI · Waltham, US
• Siying LIU · Malden, US
• Adam Looker · Newton, US
• Brad D. Maxwell · Holliston, US
• John Patrick Maxwell · Hingham, US
• Ales Medek · Winchester, US
• Philippe Marcel Nuhant · Milton Village, US
• Kirk Overhoff · Lynn, US

Key dates

• Filing date: Oct 16, 2023
• Grant date: Jun 17, 2025
• Expiry date: Oct 16, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.